Listed by the USPTO as PATTERSON, SARAH COOPER
Tech Center 1600 • Art Units: 1600 1675
This examiner grants 56% of resolved cases
PATTERSON, SARAH COOPER has resolved 43 cases, with an allowance rate of 55.8% and a median of 1492 days to allowance. The interview lift is 53.6%, so interview activity has a substantial association with allowance results in this record.
The profile includes The Regents of the University of California, University of Massachusetts, and The Regents of the University of Michigan among the recorded companies. Listed firms include Casimir Jones, S.C., WILSON SONSINI GOODRICH & ROSATI, and BOZICEVIC, FIELD & FRANCIS LLP. The 1492-day median supports early attention to prosecution timing.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630321 | DETECTION OF MEDIATORS OF DOPAMINE TRANSMISSION | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17639525 | METHODS OF TREATING KRAS MUTANT CANCERS | Non-Final OA | The Regents of the University of California |
| 17762980 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | Non-Final OA | The Regents of the University of Michigan |
| 18302630 | METHOD OF CREATING HUMAN PLURIPOTENT STEM CELL DERIVED BRAIN PERICYTE-LIKE CELLS | Final Rejection | Wisconsin Alumni Research Foundation |
| 17776524 | TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS | Non-Final OA | University of Virginia Patent Foundation |
| 17587465 | MOLECULE SPECIFICALLY ACTING IN A TISSUE WHERE A CELL DEATH IS BEING OBSERVED | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 17617165 | RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N | Non-Final OA | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 17909658 | COMBINED USE OF CTB006 AND PONATINIB | Final Rejection | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.8% of resolved applications examined by Sarah Cooper Patterson were allowed (43 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +53.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sarah Cooper Patterson took 1,492 days on average from filing to allowance.
Sarah Cooper Patterson examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).